Thailand · Delayed Price · Currency is THB X Bioscience PCL Statistics
Total Valuation
BKK:XBIO has a market cap or net worth of THB 851.46 million. The enterprise value is 1.04 billion.
| Market Cap | 851.46M |
| Enterprise Value | 1.04B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BKK:XBIO has 12.16 billion shares outstanding. The number of shares has increased by 216.98% in one year.
| Current Share Class | 12.16B |
| Shares Outstanding | 12.16B |
| Shares Change (YoY) | +216.98% |
| Shares Change (QoQ) | -68.87% |
| Owned by Insiders (%) | 81.43% |
| Owned by Institutions (%) | n/a |
| Float | 2.25B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.01 |
| PB Ratio | 2.38 |
| P/TBV Ratio | 3.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.36.
| Current Ratio | 1.30 |
| Quick Ratio | 0.27 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.37 |
| Interest Coverage | -35.01 |
Financial Efficiency
Return on equity (ROE) is -180.44% and return on invested capital (ROIC) is -155.64%.
| Return on Equity (ROE) | -180.44% |
| Return on Assets (ROA) | -59.97% |
| Return on Invested Capital (ROIC) | -155.64% |
| Return on Capital Employed (ROCE) | -203.55% |
| Weighted Average Cost of Capital (WACC) | 4.30% |
| Revenue Per Employee | 532,572 |
| Profits Per Employee | -1.80M |
| Employee Count | 399 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 24.32 |
Taxes
| Income Tax | -13.86M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.06% in the last 52 weeks. The beta is -0.23, so BKK:XBIO's price volatility has been lower than the market average.
| Beta (5Y) | -0.23 |
| 52-Week Price Change | -97.06% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.09 |
| Relative Strength Index (RSI) | 47.24 |
| Average Volume (20 Days) | 2,970,620 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BKK:XBIO had revenue of THB 212.50 million and -718.74 million in losses. Loss per share was -0.20.
| Revenue | 212.50M |
| Gross Profit | 83.88M |
| Operating Income | -748.21M |
| Pretax Income | -716.48M |
| Net Income | -718.74M |
| EBITDA | -733.73M |
| EBIT | -748.21M |
| Loss Per Share | -0.20 |
Balance Sheet
The company has 5.78 million in cash and 129.26 million in debt, with a net cash position of -123.48 million or -0.01 per share.
| Cash & Cash Equivalents | 5.78M |
| Total Debt | 129.26M |
| Net Cash | -123.48M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | 357.89M |
| Book Value Per Share | 0.02 |
| Working Capital | 82.16M |
Cash Flow
In the last 12 months, operating cash flow was -179.19 million and capital expenditures -172.82 million, giving a free cash flow of -352.01 million.
| Operating Cash Flow | -179.19M |
| Capital Expenditures | -172.82M |
| Depreciation & Amortization | 14.48M |
| Net Borrowing | -142.65M |
| Free Cash Flow | -352.01M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | 39.48% |
| Operating Margin | -352.11% |
| Pretax Margin | -337.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BKK:XBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -216.98% |
| Shareholder Yield | -216.98% |
| Earnings Yield | -84.41% |
| FCF Yield | -41.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 3, 2025. It was a reverse split with a ratio of 0.1428571429.
| Last Split Date | Oct 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1428571429 |
Scores
BKK:XBIO has an Altman Z-Score of -7.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.25 |
| Piotroski F-Score | 2 |